An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →
HDT Bio receives $5.2 million in Phase 1 funding from ARPA-H to develop an automated platform for personalized RNA medicines, with a total potential value of up to $39.5 million.
Sep 16, 2026•about 2 hours ago
Seattle
Description
HDT Bio, a Seattle-based biotechnology company, has been awarded an Other Transaction Agreement by ARPA-H. The award consists of $5.2 million for Phase 1 funding, aimed at creating an automated system for personalized RNA medicines. The program will focus on developing individualized cancer immunotherapies. The total potential value of the award could reach up to $39.5 million.
Company Information
Company
Hdt Bio
Location
Seattle, Washington, United States
About
ABOUT HDT BIO CORP: HDT Bio Corp’s mission is to bring immunotherapies to people around the world. With a focus on RNA, formulation, and adjuvant technologies, HDT Bio is developing biotherapeutics for oncology and infectious disease applications. HDT Bio simultaneously works to integrate therapeutic approaches for first-in-class medicines while building on decades of development experience with well-established pharmaceutical ingredients. The resulting products are poised to significantly improve the lives of millions of people worldwide and to provide access to lifesaving therapies for underserved populations. One of the company’s core technologies, RNA/LION™, combines formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses for therapy or vaccination. http://hdt.bio
Seattle